| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SID 26681509 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | BRD9647 | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | BRD-K84807411 | CTRPv2 | pan-cancer | AAC | -0.063 | 0.4 |
| mRNA | BMS-270394 | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | -0.046 | 0.4 |
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.4 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |